Skip to main content
Top
Published in: Digestive Diseases and Sciences 4/2018

01-04-2018 | Original Article

Effect of Bifidobacterium infantis 35624 (Align) on the Lactulose Breath Test for Small Intestinal Bacterial Overgrowth

Authors: Krishma Kumar, Mohammed Saadi, Frederick V. Ramsey, Ron Schey, Henry P. Parkman

Published in: Digestive Diseases and Sciences | Issue 4/2018

Login to get access

Abstract

Background

Small intestinal bacterial overgrowth (SIBO) may cause symptoms in patients with abdominal bloating, distension, and gas. SIBO can be assessed using the lactulose breath test (LBT). A commonly used probiotic supplement is Align containing Bifidobacterium infantis 35624. The aim of this study was to determine the effect of B. infantis 35624 on hydrogen and methane excretion during LBT.

Methods

Healthy subjects underwent LBT before and after 2 weeks of daily Align administration. Hydrogen and methane concentrations were measured for each breath sample. Results are expressed as mean ± SE and analyzed using repeated measures ANCOVA. A breath test was considered positive if hydrogen and/or methane increased > 20 ppm above baseline by 90 min of the test or if a dual hydrogen peak was present.

Results

Nineteen healthy subjects were studied. Hydrogen levels were similar pre- and post-probiotic across the 3-h study (p = 0.768). In contrast, methane levels were significantly higher with probiotic administration (p = 0.012). A rise in methane > 20 ppm was seen in three subjects pre-probiotic but six post-probiotic. Of the 19 subjects, an “abnormal” LBT pre-probiotic was present in ten subjects and during the probiotic, 13 were abnormal.

Conclusions

This study found that 2 weeks of B. infantis 35624 (Align) supplementation affects LBT assessment for SIBO by significantly increasing methane, but not hydrogen, excretion after lactulose administration. Methane levels reached values that would be considered positive for SIBO patients. This study suggests that patients undergoing LBT should discontinue probiotics prior to the test as these supplements may alter the test results.
Literature
1.
go back to reference Di Cerbo A, Palmieri B, Aponte M, Morales-Medina JC, Iannitti T. Mechanisms and therapeutic effectiveness of lactobacilli. J Clin Pathol. 2016;69:187–203.CrossRefPubMed Di Cerbo A, Palmieri B, Aponte M, Morales-Medina JC, Iannitti T. Mechanisms and therapeutic effectiveness of lactobacilli. J Clin Pathol. 2016;69:187–203.CrossRefPubMed
2.
go back to reference Boltin D, Perets TT, Shporn E, et al. Rifaximin for small intestinal bacterial overgrowth in patients without irritable bowel syndrome. Ann Clin Microbiol Antimicrob. 2014;13:49.CrossRefPubMedPubMedCentral Boltin D, Perets TT, Shporn E, et al. Rifaximin for small intestinal bacterial overgrowth in patients without irritable bowel syndrome. Ann Clin Microbiol Antimicrob. 2014;13:49.CrossRefPubMedPubMedCentral
3.
go back to reference George NS, Sankineni A, Parkman HP. Small intestinal bacterial overgrowth in gastroparesis. Dig Dis Sci. 2014;59:645–652.CrossRefPubMed George NS, Sankineni A, Parkman HP. Small intestinal bacterial overgrowth in gastroparesis. Dig Dis Sci. 2014;59:645–652.CrossRefPubMed
4.
go back to reference Saad RJ, Chey WD. Breath testing for small intestinal bacterial overgrowth: maximizing test accuracy. Clin Gastroenterol Hepatol. 2014;12:1964–1972. (quiz e1119–1920).CrossRefPubMed Saad RJ, Chey WD. Breath testing for small intestinal bacterial overgrowth: maximizing test accuracy. Clin Gastroenterol Hepatol. 2014;12:1964–1972. (quiz e1119–1920).CrossRefPubMed
5.
go back to reference Whorwell PJ. Do probiotics improve symptoms in patients with irritable bowel syndrome? Ther Adv Gastroenterol. 2009;2:37–44.CrossRef Whorwell PJ. Do probiotics improve symptoms in patients with irritable bowel syndrome? Ther Adv Gastroenterol. 2009;2:37–44.CrossRef
6.
go back to reference Charbonneau D, Gibb RD, Quigley EM. Fecal excretion of Bifidobacterium infantis 35624 and changes in fecal microbiota after eight weeks of oral supplementation with encapsulated probiotic. Gut Microbes. 2013;4:201–211.CrossRefPubMedPubMedCentral Charbonneau D, Gibb RD, Quigley EM. Fecal excretion of Bifidobacterium infantis 35624 and changes in fecal microbiota after eight weeks of oral supplementation with encapsulated probiotic. Gut Microbes. 2013;4:201–211.CrossRefPubMedPubMedCentral
7.
go back to reference van Baarlen P, Troost F, van der Meer C, et al. Human mucosal in vivo transcriptome responses to three lactobacilli indicate how probiotics may modulate human cellular pathways. Proc Natl Acad Sci USA. 2011;108:4562–4569.CrossRefPubMed van Baarlen P, Troost F, van der Meer C, et al. Human mucosal in vivo transcriptome responses to three lactobacilli indicate how probiotics may modulate human cellular pathways. Proc Natl Acad Sci USA. 2011;108:4562–4569.CrossRefPubMed
8.
go back to reference O’Toole PW, Cooney JC. Probiotic bacteria influence the composition and function of the intestinal microbiota. Interdiscip. Perspect Infect Dis. 2008;2008:175285.PubMedPubMedCentral O’Toole PW, Cooney JC. Probiotic bacteria influence the composition and function of the intestinal microbiota. Interdiscip. Perspect Infect Dis. 2008;2008:175285.PubMedPubMedCentral
9.
go back to reference Rentz AM, Kahrilas P, Stanghellini V, et al. Development and psychometric evaluation of the patient assessment of upper gastrointestinal symptom severity index (PAGI-SYM) in patients with upper gastrointestinal disorders. Qual Life Res. 2004;13:1737–1749.CrossRefPubMed Rentz AM, Kahrilas P, Stanghellini V, et al. Development and psychometric evaluation of the patient assessment of upper gastrointestinal symptom severity index (PAGI-SYM) in patients with upper gastrointestinal disorders. Qual Life Res. 2004;13:1737–1749.CrossRefPubMed
11.
go back to reference Floch MH. Use of diet and probiotic therapy in the irritable bowel syndrome: analysis of the literature. J Clin Gastroenterol. 2005;39:S243–S246.CrossRefPubMed Floch MH. Use of diet and probiotic therapy in the irritable bowel syndrome: analysis of the literature. J Clin Gastroenterol. 2005;39:S243–S246.CrossRefPubMed
12.
13.
go back to reference Rezaie A, Pimentel M, Rao SS. How to Test and Treat Small Intestinal Bacterial Overgrowth: an Evidence-Based Approach. Curr Gastroenterol Rep. 2016;18:8.CrossRefPubMed Rezaie A, Pimentel M, Rao SS. How to Test and Treat Small Intestinal Bacterial Overgrowth: an Evidence-Based Approach. Curr Gastroenterol Rep. 2016;18:8.CrossRefPubMed
14.
go back to reference McFarland LV. Evidence-based review of probiotics for antibiotic-associated diarrhea and Clostridium difficile infections. Anaerobe. 2009;15:274–280.CrossRefPubMed McFarland LV. Evidence-based review of probiotics for antibiotic-associated diarrhea and Clostridium difficile infections. Anaerobe. 2009;15:274–280.CrossRefPubMed
Metadata
Title
Effect of Bifidobacterium infantis 35624 (Align) on the Lactulose Breath Test for Small Intestinal Bacterial Overgrowth
Authors
Krishma Kumar
Mohammed Saadi
Frederick V. Ramsey
Ron Schey
Henry P. Parkman
Publication date
01-04-2018
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 4/2018
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-018-4945-3

Other articles of this Issue 4/2018

Digestive Diseases and Sciences 4/2018 Go to the issue